Jump to content
Knowledge Hub

FDA Launches Super Intelligence Hub to Support AI Innovation and Regulatory Oversight

17th November 2026

Summary:

The US Food and Drug Administration (FDA) has launched a dedicated Super Intelligence (SI) hub, bringing together resources and guidance on the development, regulation and use of artificial intelligence across FDA-regulated products. The hub covers applications in medicines, biologics, medical devices and other regulated sectors, providing information to support safe, effective and high-quality innovation. It also outlines how the FDA is using SI tools internally to improve efficiency in scientific reviews, inspections and investigations, while emphasising that regulatory decisions remain the responsibility of agency staff. Two dedicated councils oversee external regulatory policy and internal operational governance, supporting consistency, accountability and responsible adoption. The initiative reflects the FDA's commitment to integrating emerging technologies into regulatory processes while maintaining appropriate oversight and public health protection.

Link: FDA and Super Intelligence

Back to Recent News

Share